| Literature DB >> 30097701 |
Le Tao1,2, Dongying Xue2, Dongxiao Shen1, Wenting Ma2, Jie Zhang2, Xuefei Wang1, Wei Zhang1, Liu Wu2, Kai Pan2, Yanqin Yang3, Zeribe C Nwosu4, Steven Dooley5, Ekihiro Seki6, Cheng Liu7,8,9.
Abstract
MicroRNA (miRNA)-mediated gene regulation contributes to liver pathophysiology, including hepatic stellate cell (HSC) activation and fibrosis progression. Here, we investigated the role of miR-942 in human liver fibrosis. The expression of miR-942, HSC activation markers, transforming growth factor-beta pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI), as well as collagen deposition, were investigated in 100 liver specimens from patients with varying degree of hepatitis B virus (HBV)-related fibrosis. Human primary HSCs and the immortalized cell line (LX2 cells) were used for functional studies. We found that miR-942 expression was upregulated in activated HSCs and correlated inversely with BAMBI expression in liver fibrosis progression. Transforming growth factor beta (TGF-β) and lipopolyssacharide (LPS), two major drivers of liver fibrosis and inflammation, induce miR-942 expression in HSCs via Smad2/3 respective NF-κB/p50 binding to the miR-942 promoter. Mechanistically, the induced miR-942 degrades BAMBI mRNA in HSCs, thereby sensitizing the cells for fibrogenic TGF-β signaling and also partly mediates LPS-induced proinflammatory HSC fate. In conclusion, the TGF-β and LPS-induced miR-942 mediates HSC activation through downregulation of BAMBI in human liver fibrosis. Our study provides new insights on the molecular mechanism of HSC activation and fibrosis.Entities:
Keywords: HSCs; Liver fibrosis; TGF-β signaling; Viral hepatitis
Mesh:
Substances:
Year: 2018 PMID: 30097701 PMCID: PMC6590087 DOI: 10.1007/s00204-018-2278-9
Source DB: PubMed Journal: Arch Toxicol ISSN: 0340-5761 Impact factor: 5.153